Physician profile
Sandhya Murthy
NPI 1720213572
$41,771.88
in general payments reported to CMS, 2019-2025
28 companies · $1,136 in 2025
The $1,136 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $1,219 · 2021: $18K · 2022: $675 · 2023: $18K · 2024: $1,238 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,540.25 |
| Food and Beverage | $2,962.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37,985.42 | 2019-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $972.41 | 2019-2024 | Verquvo |
| Medtronic, INC. | $685.67 | 2023-2025 | Endurant Iis, Valiant Captivia |
| Arteriocyte Medical Systems, INC. | $303.39 | 2024 | Magellan |
| Actelion Pharmaceuticals US, INC. | $261.88 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $182.99 | 2020-2021 | |
| Edwards Lifesciences Corporation | $160.89 | 2024-2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $134.77 | 2025 | Onpattro |
| Cvrx, INC. | $123.53 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $119.41 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $115.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.52 | 2023-2025 | Livtencity |
| E.R. Squibb & Sons, L.L.C. | $87.10 | 2024 | Eliquis, Camzyos |
| Welch Allyn | $81.50 | 2021 | |
| Scpharmaceuticals INC. | $77.32 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.27 | 2020-2025 | |
| Abiomed | $64.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.04 | 2025 | |
| Celgene Corporation | $45.72 | 2023-2024 | Camzyos |
| Endotronix, INC. | $28.47 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| Philips North America LLC | $23.23 | 2025 | Extended Holter |
| Amgen INC. | $22.93 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.65 | 2024 | Lifevest |
| Genentech USA, INC. | $18.24 | 2022 | |
| Vifor Pharma, INC. | $17.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.02 | 2024 | Xarelto |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.